The highly anticipated Retatrutide 20mg device, a novel dual GIP and GLP-1 target , is currently being assessed by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Full availability https://socialrus.com/story25941222/retatrutide-20mg-pen-uk-availability-developments